Studies in KRAS-mutant lung and pancreatic adenocarcinoma and in KRAS-amplified gastric carcinoma reveal that SHP2 inhibition augments the antitumor effect of MEK inhibitor treatment.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Signal Transduction and Targeted Therapy Open Access 23 May 2023
-
The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
Journal of Experimental & Clinical Cancer Research Open Access 19 January 2022
-
Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes
npj Precision Oncology Open Access 29 November 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Stephen, A. G., Esposito, D., Bagni, R. K. & McCormick, F. Cancer Cell 25, 272–281 (2014).
Mainardi, S. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0023-9 (2018).
Ruess, D. A. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0024-8 (2018).
Wong, G. S. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0022-x (2018).
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. Nature 503, 548–551 (2013).
Patricelli, M. P. et al. Cancer Discov. 6, 316–329 (2016).
Lito, P. et al. Cancer Cell 25, 697–710 (2014).
Ran, H., Tsutsumi, R., Araki, T. & Neel, B. G. Cancer Cell 30, 194–196 (2016).
Chen, Y. N. et al. Nature 535, 148–152 (2016).
Dardaei, L. et al. Nat. Med. 24, 512–517 (2018).
Drosten, M. et al. EMBO J. 29, 1091–1104 (2010).
Lito, P., Solomon, M., Li, L. S., Hansen, R. & Rosen, N. Science 351, 604–608 (2016).
Acknowledgements
P.L. is supported by the National Institutes of Health (K08 CA191082-01A1), the Damon Runyon Cancer Research Foundation (Clinical Investigator Award), the LUNGevity Foundation (Career Development Award) and the V Foundation (Translational Grant).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Mai, T.T., Lito, P. A treatment strategy for KRAS-driven tumors. Nat Med 24, 902–904 (2018). https://doi.org/10.1038/s41591-018-0111-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-018-0111-x
This article is cited by
-
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Signal Transduction and Targeted Therapy (2023)
-
The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
Journal of Experimental & Clinical Cancer Research (2022)
-
Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes
npj Precision Oncology (2021)
-
The role of the glutamine transporter ASCT2 in antineoplastic therapy
Cancer Chemotherapy and Pharmacology (2021)
-
RAF kinase dimerization: implications for drug discovery and clinical outcomes
Oncogene (2020)